GIM
IART icon

Glenmede Investment Management’s Integra LifeSciences IART Stock Holding History

Glenmede Investment Management’s Portfolio IART Stock Details IART Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q3 		$12.1M Buy
842,430
+160,238
+23% +$2.2M 0.06% 308
2025
Q2 		$8.37M Buy
+682,192
New +$9.91M 0.04% 379

Other funds holding IART

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RCMNY
Rubric Capital Management (New York) New York $9.44B AUM 68.42% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Fuller & Thaler Asset Management
Fuller & Thaler Asset Management San Mateo, California $29.7B AUM 43.33% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
PCMI
Paradigm Capital Management Inc Albany, New York $2.61B AUM 78.58% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Glenmede Investment Management's IART Position: Q3 2025 in Review

Glenmede Investment Management increased its Integra LifeSciences (IART) stake by 23% in Q3 2025, buying an estimated $2.2M and bringing the position to 842,430 shares worth $12.1M. The position accounts for 0.06% of the portfolio, ranked #308.

Glenmede Investment Management first reported a position in IART in Q2 2025 and has held it in 2 quarters since. 207 funds tracked by Wall St. Rank hold IART as of Q3 2025.

  • Glenmede Investment Management held 842,430 shares of Integra LifeSciences worth $12.1M as of Q3 2025.
  • Glenmede Investment Management bought 160,238 Integra LifeSciences shares in Q3 2025, an estimated $2.2M.
  • Integra LifeSciences made up 0.06% of Glenmede Investment Management's portfolio in Q3 2025, its #308 holding.
  • Glenmede Investment Management first reported a position in Integra LifeSciences in Q2 2025 and has held it in 2 quarters since.
  • 207 funds tracked by Wall St. Rank held Integra LifeSciences as of Q3 2025.

Based on Glenmede Investment Management's 13F filing for Q3 2025, filed 13 Nov 2025.